Drugs / PLX51107
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04022785 | Sep 2019 → Oct 2022 | acute myeloid leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02683395 | Mar 2016 → Sep 2018 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | Plexxikon | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04910152 | Apr 2022 → Sep 2023 | acute graft versus host disease | Hannah Choe, MD | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLX51107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04022785 ↗ |
| Known as | Brd4 inhibitor plx51107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4521078 ↗ |
| Action | Inhibit | “PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT04022785 ↗ |
| Modality | Small molecule | “PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor” NCT04910152 ↗ |
| Route | Oral | “PLX51107 orally (PO) once daily” NCT04022785 ↗ |
| Target | BRD4 | “BRD4 Inhibitor PLX51107” NCT04022785 ↗ |